European Renal Best Practice
October 22, 2012

The prevalence of major depression in stage 5 chronic kidney disease (CKD) is high. Patients with CKD who are depressed have a worse quality of life, are hospitalized more often and die sooner than those who are not depressed. Antidepressant drugs are effective in the general population, but whether they improve outcomes in CKD is uncertain. Drug pharmacokinetics are altered in CKD, which may necessitate dose adjustment. This document provides an in-depth review of pharmacokinetics and effectiveness of different ant-depressive medications.

download PDF document